Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
publishDate:"[2010 TO 2019]"
topic_facet:"Medical Condition: Multiple Myeloma MedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2010+TO+2019%5D%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2010+TO+2019%5D%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=publishDate%3A%22%5B2010+TO+2019%5D%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
PubPharm (14)
1
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
2
Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma : A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
3
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
4
Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma : A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
5
A Clinical Study to Compare Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Bone Marrow Cancer and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy : A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
6
A Clinical Study to Compare Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Bone Marrow Cancer and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy : A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
enthalten in:
WHO International Clinical Trials Registry Platform
| 2019
Wird geladen...
7
A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and Dexamethasone (VRd) in participants with Previously Untreated Multiple Myeloma : A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy - The Perseus trial
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
8
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib. : Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib. - EMN11/HO114
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
9
A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and Dexamethasone (VRd) in participants with Previously Untreated Multiple Myeloma : A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy - The Perseus trial
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
10
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib. : Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib. - EMN11/HO114
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Erscheinungsjahr: 2010-2019
Filter aufheben
Thema: Medical Condition: Multiple Myeloma MedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
14
Aufsätze
14
E-Artikel
14
E-Ressourcen
Zeitschriftentitel
14
WHO International Clinical Trials Registry Plat...
Thema
14
610
Medical Condition: Multiple Myeloma MedDRA vers...
14
Recruitment Status: Authorised-recruitment may ...
14
Study Type: Interventional
8
Phase: Phase 2
6
Phase: Phase 3
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2010-2019
6
2019
8
2018
Erscheinungsjahr(e)
Von:
Bis:
Sprache
14
Englisch
Haven't found what you're looking for?
Wird geladen...